Navigation Links
NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
Date:10/21/2008

Findings confirm that NanoBio's nanoemulsion technology is effective when

used in therapeutic applications and vaccines

ANN ARBOR, Mich., Oct. 21 /PRNewswire/ -- NanoBio Corporation announced today that it will present compelling new data in nine presentations that detail key milestones in its clinical and preclinical development programs in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal influenza vaccine during the joint meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, DC, October 25-28.

The company's presentation schedule during the conference is detailed below. NanoBio will also exhibit at corporate booth #408.

Sunday, October 26, 2008

11:15 a.m. - 12:15 p.m. A Novel Nanoemulsion Adjuvant Enhancing the Immune Response to beta-propiolactone Inactivated Influenza Virus Using a Nasal Route in a Ferret Model, Poster #G-1194

Monday, October 27, 2008

11:15 a.m. - 12:15 p.m. Novel Nanoemulsion NB-001 Permeates Skin by the Follicular Route, Poster #A-1898

11:15 a.m. - 12:15 p.m. NB-002, a Novel Nanoemulsion with Anti-Dermatophyte Activity, Poster #M-2134

11:15 a.m. - 12:15 p.m. Mechanism of Skin Penetration and Distribution of a Novel Nanoemulsion, Poster #M-2135

12:15 p.m. - 1:15 p.m. Safety, Tolerability and Pharmacokinetics of NB-001 in a Phase 2 Dose-Ranging Trial in Subjects with Recurrent Herpes Labialis, Presentation #V-3539

12:15 p.m. - 1:15 p.m. NB-001, A Novel Nanoemulsion Active Against Acyclovir (ACV)- and Foscarnet (FOS)-Resistant Herpes Simplex Virus (HSV) 1 and 2, Poster #V-3538

Tuesday, October 28, 2008

9:00 a.m. - 9:15 a.m. Oral Presentation: Subject-Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Topical Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis

11:15 a.m. - 12:15 p.m. Novel Nanoemulsion Antimicrobials Tested Against Nine Gram-Positive Species, Poster #F1-3944

11:15 a.m. - 12:15 p.m. Antimicrobial Activity of Nanoemulsions Tested Against Seven Gram-Negative Species, Poster #F1-3945

About NanoBio:

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daniel B. Dubin, M.D., Joins NanoBio Corp.s Board of Directors
2. FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008
3. David M. Stout Joins NanoBio Corporations Board of Directors
4. Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research
5. NanoBio Expands Drug Development Team for Its Anti-Infective Products
6. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
7. Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call
8. NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
9. BioElectronics Announces Significant Progress in Canadian and International Distribution
10. Instrumentation Laboratory Announces Passion & Results Awards Program
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... --> ... oncology company developing next generation cancer therapeutics that ... that chairman emeritus of Tata Sons Limited, Mr ... as part of the first close of Invictus,s ... Capital and Aarin Capital. http://photos.prnewswire.com/prnh/20150923/766442 ) ...
(Date:2/8/2016)... 2016  BioElectronics Corporation (OTC Pink: BIEL), the ... that it is responding to a notice of ... and Exchange Commission posted on the agency website.  ... the Board of BioElectronics Corporation and the Edward ... The Fuqua School of Business, Duke University.   ...
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. , an ... technology, today announced the availability of AllegroGraph 6, the leading Semantic Graph Database ... Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph Database to ...
(Date:2/8/2016)... Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, Feb. 4, ... Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create a smarter, ...
Breaking Biology Technology:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
Breaking Biology News(10 mins):